2025. Durable maintenance of EASI-90 with amlitelimab in adults with moderate-to-severe atopic dermatitis: 52-week results from the STREAM-AD phase 2b trial. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s606. DOI:https://doi.org/10.25251/yhn4cs07.